Santander International Selects Temenos and Syncordis to Launch its Digital Banking Platform in the Cloud and Become “future-ready”
6.4.2021 09:30:00 EEST | Business Wire | Press release
Syncordis, the global Temenos implementation partner and product experts, and Temenos (SIX: TEMN), the banking software company, announced that Santander International, part of the Banco Santander group, has selected Temenos SaaS, implemented by Syncordis, to power-up its core banking platform transformation.
Syncordis will help Santander International, which has branches in Jersey and the Isle of Man, to transform its banking, savings and mortgage products IT infrastructure from an on-premise solution to cloud-native Temenos SaaS. This will enable Santander International to benefit from the security, resilience and elastic scalability of the Microsoft Azure cloud.
Moving to the Temenos cloud-native and API-first digital banking platform with pre-configured banking and mortgages functionality will enable the bank to build and launch products faster and deliver enhanced digital experiences with streamlined customer journeys.
Syncordis has been selected as the system integrator and implementation partner to lead the core banking implementation and modernization project with a new digital banking eco-system. Adopting an agile implementation approach to complete the project delivery in the shortest timeframe, the bank’s customers will benefit from a smooth transition to Temenos’ next generation digital banking solution.
James Pountney, Chief Executive Officer Santander International, commented:
“In challenging times such as these, it is more vital than ever to be able to adapt to changing business and customer requirements simply, safely and swiftly. By working with Temenos and Syncordis we will be able to future-proof our digital banking platform which will enable us to provide our valued customers with outstanding service and a seamless customer experience.”
Hemal Jayasinghe, Chief Business Officer / Regional Director UK & NORDICS, Syncordis, said:
“We are excited to strategically partner with Santander International to modernize their core banking operations and drive their digitization journey. Innovation and the willingness to transform are key in today’s ever-changing world. With Temenos’ powerful cloud technology and Syncordis’ extensive implementation expertise, Santander International will be enabled to power their digital banking capabilities, provide an excellent and modern experience to their customers and future-proof their business.”
David Macdonald, President - Europe, Temenos, said:
“We’re excited to be working with Santander International to help redefine their customer experience. We see a growing momentum of banks both globally and in Europe choose Temenos as the most advanced cloud technology in the market to break free from legacy systems. Temenos SaaS delivers speed and agility while providing the security and resilience that a modern digital bank needs. We’re proud to be part of this evolution.”
Notes for Editors:
About Santander International:
Santander International is the trading name of the Jersey and Isle of Man branches of Santander Financial Services plc, a wholly owned subsidiary of Santander UK Group Holdings plc which is part of the Banco Santander group.
Santander International offers banking and savings accounts to Channel Island and Isle of Man residents, UK residents, UK expatriates, foreign expatriates and international customers. Santander International also offer mortgages on Jersey and Isle of Man properties and Corporate Banking solutions for Channel Island and Isle of Man domiciled companies. www.santanderinternational.co.uk
About Syncordis:
Syncordis, a Luxembourg based LTI Company, delivers high-quality end-to-end implementation and system integration projects with an exclusive focus on Temenos banking software such as Temenos Infinity, Temenos Transact, Temenos Fund Administration, Temenos Infinity Wealth and Temenos DataSource. Syncordis is also the only Temenos global partner that is fully dedicated to Temenos services with capabilities to support all Temenos software suites. With 12 offices across the globe, 500+ experts and complementary services like SaaS and regulated production support services, Syncordis enables its international clients to master their digital transformation. This makes Syncordis one of the one-stop service partners for Temenos clients worldwide. For more information, please visit www.syncordisconsulting.com
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210405005020/en/
Contact information
Media Contact for Syncordis:
Clara Bechler
Marketing & Communication
T +49 40 369 835 12
E cbechler@syncordisconsulting.com
Media Contact for Santander International:
Susan Clark
Marketing & Communications
T +44 1534 828 011
susan.clark@santanderinternational.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom